Home

Pharma China Web Edition

Pharma China Archives

Online Databases

Subscription/Order/Info

Event Calendar

China Pharma Providers

About Us

	News     The Market     Industry News     Regulatory News     General Health     Legal/IPR News     Product/R&D News     API/Bulk Drug News     People in the News     Other News     Top News Worldwide Feature articles     Editorials     Commentaries     Expert Opinions     Interviews     Case Studies     Company Profiles     Editor´s Picks Full Text Title

The Market Industry News Regulatory News General Health Legal/IPR News Product/R&D News API/Bulk Drug News People in the News Other News Top News Worldwide Editorials Commentaries Expert Opinions Interviews Case Studies Company Profiles Editor´s Picks

China Sends Mixed Signals for Healthcare as Outlook Shift from Cautious Optimism... Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on mixed signals for Chinese pharma recently, as well as dev... (3/1/2019) Shine News: MAH Program A Shot in the Arm for Chinese Pharmaceutical Industry (3/19/2019) 5 Key Elements of Chinese Biopharma's "Cambrian Explosion" (3/17/2019) A Merck Cancer Treatment Has a Big Opportunity in China, Analyst Says (3/13/2019) China Sends Mixed Signals for Healthcare as Outlook Shift from Cautious Optimism to Cautious Pessimism for Many (3/1/2019) New IFPMA Code of Practice Tightens Restrictions on Gifts (with Case on RDPAC Code Changes) (2/27/2019) Chinese Biotech Feels Chill in Harsh Winter for Venture Capital (2/26/2019) More Changes Possible in China's Patent Law Amendment? (2/21/2019) Whatever The Outcome Of U.S.-China Trade Talks, Global Supply Chains Are Set To Change (2/21/2019) PharmExec - Mixed Outlook for China Life Sciences (2/16/2019) PharmExec - China: A Change in Attitude (2/16/2019) PharmExec - New Roads to China (2/16/2019) China's Biotechnology Development: The Role of U.S. and Other Foreign Engagement (2/14/2019) Review of Chinese Pharma Deals, R&D and Regulatory Developments in 2018 (2/13/2019) Chinese Pharma under Cloud Again in the Supposedly Lucky Year of the Pig (2/12/2019) SAMR Fines Hunan Er-Kang And Henan Jiushi CNY 10M for Unfair Pricing Of Chlorpheniramine API (2/8/2019) CanSinoBio to Launch $161M Hong Kong IPO...  (3/19/2019) MilliporeSigma to Collaborate with GenSc...  (3/19/2019) ImmunoBiology and CNBG Enter Licensing P...  (3/19/2019) Korean Pharma Il-yang and Hanmi Report R...  (3/19/2019) Takeda to Invest CNY 110M into Expanding...  (3/19/2019) Merck KGaA Aims to Double China Sales by...  (3/19/2019) Xynomic Pharma Gains Phase III Trial App...  (3/17/2019) NHSA Releases 2018 Healthcare Security S...  (3/15/2019) Upcoming Event: 4th Asean Pharma Packagi...  (3/15/2019) (free) Upcoming Event: Precision Medicine Congr...  (3/15/2019) (free) Recent Executive Moves  (3/15/2019) Upcoming Event: 3rd Publishers Summit  (3/15/2019) (free) Upcoming Event: 3rd edition of the Shang...  (3/15/2019) (free) Astellas Launches Teijin’s Gout Medicin...  (3/15/2019) Pharma China Annual Forum 2019 (April 9,...  (3/15/2019) (free) IQVIA: Global Pharma to Grow Slower in the Next Five Yea... Pfizer and GSK Announce JV to Create a Global Consumer H... Top 25 Global Pharmaceutical Companies by Market Cap 201... CANbridge Receives IND Approval to Commence CAN008 Phase... Global Contract Pharmaceutical Manufacturing Market to R... Chinese Diabetes Drug Market Continues to be Dominated by MNCs ... IQVIA/McKinsey: Generics Continue to Dominate Chinese Pharma Ma... IQVIA Publishes Report on Orphan Drug Access in China as the Co... Sinohealth: Chinese Retail Pharmacy Sales Slowed to the Lowest ... Nicholas Hall Reports 6% Growth for Chinese OTC VMS Market in 2... CanSinoBio to Launch $161M Hong Kong IPO MilliporeSigma to Collaborate with GenScript to Accelerate C... ImmunoBiology and CNBG Enter Licensing Pact to Co-Develop Va... Korean Pharma Il-yang and Hanmi Report Robust Sales Growth i... Takeda to Invest CNY 110M into Expanding Its Chinese Manufac... CDE Solicits Public Comments on Clinical Trial Guideline... Chongqing Approved to Set Up Destination Port for First-... CDE Seeks Comments on Draft ICH Guideline M8 and E2F Chinese Generic Drug Applications Rebound in 2018 After ... CDE Publicizes 8+3 More Drug Applications To Be Granted ... USTR's 2018 Report for China's WTO Compliance Highlight IP I... Report: China Tightens IP Protection and Expands Patent Refo... China Claims Steady Progress in Key Indicators of IP in 2018... China: Gene-Editing Scientist Broke Laws for ‘Personal Fame... Hogan Lovells: Pharma Companies May Benefit from Proposed Pa... Huahai Pharma Involved In Another Blood Pressure Drug Re... Novo Nordisk Pharmatech A/S signs Asia Pacific distribut... Trade Bodies Warns API Supply Chain Disruptions from Chi... India Seeks to Reduce Reliance on Chinese Pharma Imports... USFDA Warns Zhejiang Huahai for Failure to Detect Valsar... CASI Pharma Announces CTA Approval for MARQIBO Novartis Reports Positive Data from Chinese Trial of Cos... Novartis Submits NDA of Latest MS Drug Siponimod in Chin... CASI Pharma Granted CTA To Conduct Clinical Trial of ZEV... Hua Medicine Initiates First Combination Study of Dorzag... NHSA Releases 2018 Healthcare Security Sector Developmen... China Faces A Daunting Healthcare Bill from Heart Diseas... Chinese Experts Warn of Rising Kidney Disease in the Cou... NHSA Issues Action Plan for 2019 NRDL Revision Large Scale/Long Term Study Confirms Correlation Between... Recent Executive Moves 42 Chinese Pharma Billionaires Made the Hurun Global Rich ... Recent Executive Moves Recent Official and Executive Moves Recent Executive Moves Upcoming Event: 4th Asean Pharma Packaging Conference Upcoming Event: Precision Medicine Congress Upcoming Event: 3rd Publishers Summit Upcoming Event: 3rd edition of the Shanghai eHealth Work... Pharma China Annual Forum 2019 (April 9, Shanghai) Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector... WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...   WiCON to Hold Pharma China Ann...   WiCON Publishes the China Phar...   WiCON Officially Publishes Chi...   WiCON Officially Publishes Chi...   WiCON and PharmaGuys Launch Ph...

© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links